FDA Clears New Alzheimer's Blood Test for Adults 55+: What Patients and Families Should Know

A newly FDA-cleared blood test could make it easier for doctors to determine whether Alzheimer's-related brain changes are behind memory and thinking problems, potentially bringing testing into more primary care offices. But the test is not meant to screen healthy adults or predict who will eventually develop dementia.

The U.S. Food and Drug Administration (FDA) has cleared the Elecsys pTau217 blood test from Roche Diagnostics to help physicians assess whether adults age 55 and older with cognitive concerns have brain changes associated with Alzheimer's disease.

The test measures phosphorylated tau 217, commonly called p-tau217, a blood biomarker strongly associated with amyloid pathology in the brain.

Unlike some traditional methods of detecting amyloid, the new test does not require a positron emission tomography (PET) brain scan or the collection of cerebrospinal fluid through a lumbar puncture.

Perhaps more significantly, the test is designed for use not only by Alzheimer's specialists but also as part of the evaluation process in primary care. That could eventually make Alzheimer's assessment more accessible for older adults who first bring memory concerns to their family doctor.

For decades, clinicians have faced significant challenges in accurately diagnosing Alzheimer's disease in its early stages." — Jared R. Brosch, M.D., a neurologist at Indiana University Health. 

Brosch noted that confirmatory tools like PET imaging and cerebrospinal fluid testing can be "costly, invasive, and not readily accessible for many patients." He said advances in blood-based biomarkers could expand access to evaluation across care settings and help clinicians identify patients earlier in the disease course, giving patients and families more information to make decisions at a critical time.

That could eventually make Alzheimer's assessment more accessible for older adults who first bring memory concerns to their family doctor, allowing treatment to start earlier, hopefully delaying the progression of symptoms.

What the New Alzheimer's Blood Test Does

Elecsys pTau217 is intended for people age 55 and older who already have signs, symptoms, or complaints of cognitive decline. It is not a general Alzheimer's screening test for people without symptoms.  

The test produces positive, intermediate, or negative results that help doctors assess the likelihood that amyloid pathology is present in the brain. Amyloid plaques are one of the defining biological features associated with Alzheimer's disease.

Roche says the test demonstrated high agreement with amyloid PET imaging during its evaluation. The test can help your doctor determine whether additional testing or a referral to a neurologist or other specialist may be appropriate. However, a blood test result by itself does not establish an Alzheimer's diagnosis.

Roche specifically says Elecsys pTau217 is not intended as a stand-alone diagnostic test. Doctors must interpret the result alongside a patient's symptoms, medical history, cognitive testing, and other clinical information.

Roger Walters, a registered nurse and medical advisor for LTC News, became a long-term care planning specialist because of his experience in nursing. Walters says that earlier detection doesn’t give us a cure for Alzheimer’s. However, Walters says it may give patients and physicians more opportunity to intervene while the disease is still in its earlier stages.

When dealing with a progressive disease, preserving function and independence for as long as possible can mean precious additional time for both the patient and their family." — Roger Walters, RN.

Why This Test Could Be Different

The biggest change may not be the technology itself. It may be access. Roche says Elecsys pTau217 can operate on more than 4,500 of its cobas laboratory instruments already installed in clinical laboratories throughout the United States.

Labcorp has announced that it will offer the test, and Quest Diagnostics also plans to make the FDA-cleared test available through its laboratory network. That existing infrastructure could eventually allow blood-based Alzheimer's testing to reach considerably more communities than specialized PET imaging or cerebrospinal fluid testing.

Joanne Pike, DrPH, president and CEO of the Alzheimer’s Association, called the clearance the latest advancement in Alzheimer’s research, saying it helps make "accurate diagnosis and the treatment and care management options that can follow" more accessible for patients and families.

Maria C. Carrillo, Ph.D., Alzheimer’s Association chief science officer and medical affairs lead, says this is real progress for a field that, for decades, had far too few tools to offer.

Each FDA clearance gives clinicians another validated option to work with when evaluating patients showing signs of cognitive impairment.” —Maria C. Carrillo, Ph.D.

The new Roche test is the fourth blood-based biomarker test for Alzheimer's disease cleared by the FDA, and the second within the past week, following Fujirebio's Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio in May 2025 and Roche's own Elecsys pTau181 in October 2025.

Roche describes Elecsys pTau217 as the first single-biomarker blood test cleared to support both ruling in and ruling out amyloid pathology using the same validated cutoffs across primary and specialty care. The pace of those clearances shows how quickly blood-based Alzheimer's testing is moving from research into clinical medicine.

What p-Tau217 Can and Cannot Tell You

The biomarker involved in the new test may sound familiar. Earlier in 2026, LTC News reported on separate research examining whether a related plasma biomarker measurement of p-tau217 could eventually help scientists estimate when Alzheimer's symptoms might emerge, years before they appear. That work, a research "clock model" that is not the same as the newly cleared diagnostic test, is still limited to research settings.

The newly cleared Elecsys test does not predict when someone will develop Alzheimer's disease. Its safety and effectiveness have not been established for predicting the future development of dementia or other neurological conditions. It is also not intended to monitor whether an Alzheimer's treatment is working.

That distinction is important. If you are cognitively healthy, you should not interpret the FDA clearance as a reason to request the test simply to learn whether Alzheimer's disease is in your future. Instead, the test is intended to help doctors evaluate people who are already experiencing cognitive concerns.

Michele Perloe, a long-term care planning specialist, tells LTC News that advances in diagnosis and treatment sometimes give people a false sense that they can put off planning for future care.

Too often, people look at medical advances and think they are a reason not to plan for long-term care. The opposite is true. We are getting better at diagnosing conditions earlier, treating disease and helping people live longer, but living longer can also mean living for years with chronic health problems or cognitive decline. Advances like this give families more information and potentially more time. That makes planning ahead even more important.” — Michele Perloe, Long-Term Care Insurance specialist.

Perloe says earlier information can give families an opportunity to discuss future care while the person affected can still participate in those decisions.

If you learn earlier that cognitive changes may be related to Alzheimer’s, you have more time to talk with your family about where you would want to receive care, who would help you and how that care would be paid for. Waiting until a crisis takes many of those choices away.” — Michele Perloe.

Walters agrees. He says that the worst time to create a long-term care plan is in the middle of a long-term care crisis.

Earlier knowledge allows families to talk about where someone wants to receive care, who they want involved, and how that care will be paid for while the patient can still be part of those decisions." — Roger Walters, RN.

Why Earlier Answers Matter for Families

About 7.4 million Americans age 65 and older are living with Alzheimer's dementia in 2026, according to the Alzheimer's Association. Without breakthroughs that prevent or cure the disease, that number could reach 13.8 million by 2060. Nearly 13 million Americans already provide unpaid care for people with Alzheimer's disease or other dementias, on top of a total of 63 million unpaid caregivers in the United States today.

A diagnosis does not stop the progression of dementia. But identifying the cause of cognitive changes earlier gives your loved one a better chance to participate in decisions about treatment, finances, legal planning, housing, and future care while they can still weigh in.

The earlier those conversations happen, the more say your loved one has in how and where they receive care.

Alzheimer's Is Increasingly Defined by Biology

Alzheimer's disease has historically been evaluated through symptoms, cognitive testing, medical history and, when necessary, specialized testing. Blood biomarkers are helping change that approach.

Researchers increasingly can identify biological evidence associated with Alzheimer's disease before or alongside the clinical assessment of dementia. That shift matters because Alzheimer's symptoms can overlap with other medical conditions.

Memory problems do not automatically mean Alzheimer's disease. Medication side effects, depression, sleep disorders, thyroid problems, vitamin deficiencies, infections and other neurological conditions can sometimes produce cognitive symptoms.

If you notice persistent changes in memory, reasoning, judgment or everyday functioning, talk to your doctor rather than assuming Alzheimer's is the cause.

Does Medicare Cover Alzheimer's Testing?

Medicare Part B covers a separate cognitive assessment and care plan services visit when your doctor needs to more thoroughly evaluate cognitive function, establish or confirm a diagnosis such as dementia or Alzheimer's disease, and develop a care plan. Medicare also generally covers medically necessary diagnostic laboratory tests ordered by a doctor or other qualified health care provider.

That said, FDA clearance does not by itself guarantee coverage for the new Elecsys pTau217 test in every circumstance. As of Aug. 25, 2026, LTC News found no coverage determination from the Centers for Medicare & Medicaid Services (CMS) specifically addressing the newly cleared Elecsys pTau217 test, so how it gets billed, whether it is covered and what you may owe out of pocket can vary by lab, region and individual plan. Employer health plans will also vary from plan to plan.

Ask your doctor and laboratory about coverage and potential costs before testing.

Diagnosis Can Be the Beginning of a Care Plan

For families, an Alzheimer's diagnosis often changes much more than the medical treatment plan. Dementia can gradually affect a person's ability to manage medications, prepare meals, drive, handle money, communicate, and safely remain alone.

Medicare can pay for medical care and certain short-term skilled services, but it generally does not pay for ongoing custodial long-term care simply because someone has Alzheimer's disease or another form of dementia.

Medicaid can pay for long-term care for people who meet financial and functional eligibility requirements. When paid care isn't available or affordable, spouses and adult children often become the primary caregivers, sometimes for years.

Other families must use personal savings unless they have Long-Term Care Insurance or a combination of resources. Memory care is expensive, according to an LTC News survey of long-term care costs. The LTC News Cost of Long-Term Care Services Calculator is the most comprehensive in the industry. You can search for current and projected future costs of extended care services by ZIP code, city, or town.

If you already own an LTC policy, remember that benefits are generally triggered by a need for help with at least two activities of daily living or by qualifying cognitive impairment. A diagnosis by itself does not necessarily trigger benefits.

Families dealing with an existing issue with a loved one who has a Long-Term Care Insurance policy can also use LTC News' free claims assistance to help navigate the claims process. LTC News partners with Amada Senior Care to provide free claim support with no cost or obligation.

Finding quality caregivers, especially memory care, can be challenging. The LTC News Caregiver Directory has over 80,000 caregivers and long-term care facilities that you can search by ZIP code.

A Rapidly Changing Alzheimer's Landscape

The FDA clearance of Elecsys pTau217 does not mean diagnosing Alzheimer's has been reduced to a single blood test. It does signal something significant. Blood-based biomarkers that only recently seemed primarily like research tools are becoming part of clinical medicine.

If you or a loved one is experiencing unexplained memory or thinking problems, this could mean the first steps toward determining whether Alzheimer's disease is involved may soon begin at a primary care office, with a simple blood draw.

For families, getting reliable answers sooner can provide something equally valuable: more time to understand what is happening, explore treatment and support options, and prepare for the care that may be needed in the years ahead.

People typically plan for the consequences of aging and future long-term care before retirement. LTC News research shows that most people purchase an LTC policy between the ages of 47 and 67. Be sure to seek help from a qualified LTC Insurance specialist to help you navigate options and find an accurate quote from all the major insurance companies offering long-term care solutions.

Learn More: How to Apply for Long-Term Care Insurance

Have you talked with your family about what you'd want if a memory concern turned out to be something more serious?